Evotec and Novo Nordisk form strategic research alliance in diabetes and obesity
Evotec AG today announced a strategic alliance with Novo Nordisk to discover and develop novel small molecule therapies to treat patients suffering from diabetes and obesity as well as co morbidities such as nonalcoholic steatohepatitis (“NASH”), cardiovascular diseases, and diabetic kidney disease.
20 September 2018
Bioagora 2018 (Copenhagen)
19 September 2018
STZ OcuTox: Drug development know-how
12 September 2018
Good industry performance lifted spirits in the HealthBIO conference